BioCopy invented the biomolecule copier. Basically it is the fusion of a Xerox and the natual information flow from DNA to protein. Imagine a master made of DNA and you are free to select the biochemistry and surfaces to get a copy in terms of DNA, RNA and protein and everything monitored label-free. This enables you also to see kinetics in a label-free imaging mode. So basically imagine a massively multiparallel Biacore, but as movie and without the disturbing gold layer and thermal drift issues.
Due to the Corona crisis we joint up forces with Sino Biological to prepare COVID19-arrays yielding 90 different RBD and S-protein mutants. With our label-free detection platform and these arrays we are capable to see not only binding patterns of diagnostic and therapeutic antibody, but we are able to run ACE2-inhibition assays. This enables us to make pseudo-neutralization tests of these antibodies and with 5 µg antibody we can see if it is usable for diagnostics or therapeutics. Where does it work and which mutant “breaks” it. With a way smaller array we already found in Summer last year that one of Regenerons may not work for some mutants. E484K was amongst them.
But now imagine to use this arrays with serum of formerly infected or vaccinated persons. This will give you basically a glance, where are the weaknesses within the immune system and which mutants may arise. You will be surprised, what is already “written” into our blood and we will share some insights. You may already have a look at https://www.youtube.com/watch?v=c9i7ffpYP_g
. Dr. Pascal Brenneisen (former CEO Novartis Switzerland, advisory board BioCopy)
. Dr. Günther Proll (former CEO Biametrics, now BioCopy Senior Scientist)
. Dr. Günter Roth (CEO of BioCopy)
(former CEO Novartis Switzerland, advisory board BioCopy)
Dr. Günther Proll
(former CEO Biametrics, now BioCopy Senior Scientist)
Dr. Günter Roth
(CEO of BioCopy)